Stay updated on Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T22:32:22.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:20:14.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study details, blocking access to the ClinicalTrials.gov entry. This reflects an access restriction rather than a content update to the study record.
    Difference
    21%
    Check dated 2026-09-19T20:59:08.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The Melanoma label along with related topics and the MedlinePlus Genetics link were removed from the page, reducing disease-focused context and external reference options presented to readers.
    Difference
    0.1%
    Check dated 2026-09-12T19:39:02.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The study record was updated with new arm descriptions, dosing details, and eligibility language, and an IPD sharing plan was added; a 'Results Posted' notice was also included to reflect recent outcomes.
    Difference
    3%
    Check dated 2026-08-29T19:56:35.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    Merck sponsor details and IPD sharing resources were added, along with related informational links. The update expands the page with governance and data-sharing context for the trial.
    Difference
    82%
    Check dated 2026-08-15T20:52:34.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Alone in Stage III Melanoma Clinical Trial page.